Navigation Links
Study finds warfarin underutilized in women
Date:12/13/2011

LEXINGTON, Ky. (Dec. 13, 2011) Dr. Rabab Mohsin, an internal medicine resident at the University of Kentucky, working with Dr. Alison Bailey of the University of Kentucky Gill Heart Institute, has discovered that the drug warfarin was underutilized in a large study group of women.

Working in conjunction with the Kentucky Women's Health Registry, Mohsin, Bailey and fellow investigators identified women who reported arrhythmia (irregular heartbeat) identification and treatment. Specifically, the investigators worked to determine whether prescription warfarin (an anti-coagulant known as a safe and effective treatment for atrial fibrillation) was being appropriately utilized among a population of Kentucky women with self-reported atrial fibrillation.

Survey data revealed that among the group of women who would be expected to be receiving warfarin, only 30 percent were receiving the drug. Notably, the research population was found to have a higher than average level of income and education as compared to other Kentucky women in their age group. Statistical analysis also revealed that older women were more likely to be taking warfarin (a mean age of 73.4 years was found for those with atrial fibrillation who were on warfarin, while the population with atrial fibrillation but without warfarin treatment had a mean age of 61.8).

Overall, Mohsin, Bailey and fellow investigators concluded that warfarin anticoagulation treatment for atrial fibrillation is underutilized in the group of Kentucky women studied, and that this underutilization is not attributable to economic or educational disparities.


'/>"/>

Contact: Allison Elliott
allison.elliott@uky.edu
University of Kentucky
Source:Eurekalert

Page: 1

Related medicine news :

1. RI Hospital receives $1.5 million grant to study treatments for body dysmorphic disorder
2. Study explores mens ability to manage fear in ways that allow them to exhibit confidence
3. JDRF-funded study seeks to reduce cardiovascular risk
4. Study Questions Use of MRI Before Back-Pain Injections
5. ADHD Drugs Dont Raise Risk of Heart Problems: Study
6. Snakes Make Your Skin Crawl? Study Suggests Why
7. Study of 2 sisters sheds light on lymphoma evolution
8. Rutgers Study: When it comes to use of dental services, not all NJ youngsters are equal
9. Patient isolation associated with hospital delirium: study
10. Ruxolinitib better at reducing myelofibrosis symptoms, study shows
11. Study favors as-needed treatment over maintenance therapy for patients with follicular lymphoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... ... March 24, 2017 , ... Shamanic healer ... for Shamanic Healing and Spiritual Awakening, proudly presents her Sacred Peru retreat ... This sacred and spiritual journey during the Summer Solstice will also be her ...
(Date:3/24/2017)... (PRWEB) , ... March 24, 2017 , ... ... two panels at the Advanced ERISA Benefit Claims Litigation seminar in Chicago, Illinois. ... the Administrative Record, The majority of cases litigated under ERISA involve claims for ...
(Date:3/24/2017)... ... March 24, 2017 , ... Empower ... upgrading their training and leads programs. , In February, 2017, Empower Brokerage introduced ... agents, Performance Partners is designed to teach how to maximize their sales efforts, ...
(Date:3/24/2017)... ... ... “Vintage and Harvest A Cultivation of Christian Love” is the creation of published author, ... his wife, Anna Marie. He and his wife are the proud parents of four ... of “Shadow and Substance.” , “Love, the agape kind, is seen as more than ...
(Date:3/23/2017)... ... 23, 2017 , ... A recent report from the National Council on Teacher ... NCTQ report suggests, based on a review of GPA and SAT/ACT requirements at 221 ... the U.S. It argues that this higher bar should be set by states, by ...
Breaking Medicine News(10 mins):
(Date:3/24/2017)... , Mar. 24, 2017 Research and Markets has ... Analysis, 2016" report to their offering. ... The IPF pipeline is very strong with a total ... & Co., Inc., Biogen and Sanofi are involved in the development of ... which one is in Phase III stage, 15 are in Phase II ...
(Date:3/24/2017)... Mar 24, 2017 Research and Markets has ... Strategic Business Report" report to their offering. ... The report provides separate comprehensive analytics for the ... Europe , Asia-Pacific , Latin ... provided for the period 2015 through 2022. Also, a six-year historic analysis ...
(Date:3/24/2017)... , March 23, 2017  Provectus Biopharmaceuticals, Inc. ... "Company"), a clinical-stage oncology and dermatology biopharmaceutical company, ... Financing Commitment Term Sheet (the "Definitive Financing") it ... of the Company,s stockholders, who are referred to ... a Form 8-K filed with the Securities and ...
Breaking Medicine Technology: